Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Eli Lilly’s (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, met their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.The patient population in the first phase III study, QWINT-2, comprised type II diabetes (T2D) patients who had never been treated with insulin before (insulin naïve). On the other hand, the phase III QWINT-4 study enrolled adults with T2D who have previously been treated with basal insulin and at least two injections ...